How to cite item

Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden

  
@article{CDT14042,
	author = {Yu Kataoka and Jordan Andrews and MyNgan Duong and Tracy Nguyen and Nisha Schwarz and Jessica Fendler and Rishi Puri and Julie Butters and Constance Keyserling and John F. Paolini and Jean-Louis Dasseux and Stephen J. Nicholls},
	title = {Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden},
	journal = {Cardiovascular Diagnosis and Therapy},
	volume = {7},
	number = {3},
	year = {2017},
	keywords = {},
	abstract = {Background: CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001. 
Methods: CHI-SQUARE compared the effect of 6 weekly infusions of CER-001 (3, 6 and 12 mg/kg) vs. placebo on coronary atherosclerosis in 369 patients with acute coronary syndrome (ACS) using serial intravascular ultrasound (IVUS). Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. 369 subjects were stratified according to the cutoff. The effect of CER-001 at different doses was compared to placebo in each group. 
Results: A B-PAV ≥30% was the optimal cutoff associated with PAV regression following CER-001 infusions. CER-001 induced PAV regression in patients with B-PAV ≥30% but not in those with B-PAV },
	issn = {2223-3660},	url = {https://cdt.amegroups.com/article/view/14042}
}